Subscriber ContentRead Preview
The medical-device maker has better prospects than critics think. Just ask uber-investor John Paulson.
Tech Trader Daily by Tiernan Ray
Subscriber Content Read Preview
With Whole Foods' stock near a two-year high, Leonard Green & Partners deftly sold about $107.4 million in shares.
Subscriber Content Read Preview
Dell, Family Dollar and Sirius XM rose. OfficeMax fell.
Subscriber Content Read Preview
Shares of the handset maker could reach $80 before long.
Subscriber Content Read Preview
Intel and Altera are seen as favorites amid tight capacity conditions.
Subscriber Content Read Preview
The financial-services firm's long-term fundamentals remain intact.
Subscriber Content Read Preview
Credit Suisse says consolidation in the sector makes sense.
Subscriber Content Read Preview
BofA Merrill finds highest bullishness since January 2006, especially in tech. Time to go the other way?
Subscriber Content Read Preview
Here are some trades to help protect the life insurer's recent Apple-beating gains.
Subscriber Content Read Preview
Japanese currency shows signs of significant weakening ahead as economy falls to No. 3 and as its debt burgeons.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
The tech titan tops our global ranking for the second straight year, followed by Amazon and Berkshire Hathaway.
Editor and President Ed Finn explains how you can use Barron's to become a better investor. Watch video
FXC | ADI | CCL | JPM | WFMI |
INTC | AMG | CML | MDT | MET |
NYX | VTI | EWP | DELL | AN |
AMD | BRCM | AAPL | ADSK | AGG |
Subscriber Content Read Preview
Slowing growth abroad will likely be a drag for the U.S.
The chief investment officer of Rosenau/Paul thinks the time is finally here for large-cap stocks with growing dividends. Here's what she's been buying.
Regardless of what path Egypt now follows, a leading analyst says the price of oil is headed toward $300 a barrel based on basic supply-and-demand forces.
With drug stocks ailing, companies like Abbott and Medtronic should start shedding non-core businesses. For investors, it would be just the right medicine.
Business ethicists and advocates for corporate social responsibility are playing a dangerous game.
This feature tracks the performance of stocks Barron's has written about during 2011 -- both favorably and critically. For stocks featured in Barron's print magazine, prices are measured from the Friday before publication date to their current price. For stocks featured on Barrons.com, prices are measured from the trading day of publication date to their current price. This list includes U.S. stocks only, including ADRs, but not foreign stocks.